Retina

Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "AMD updates: Staying current with its landscape," which he co-presented with Jay Haynie, OD, FAAO.

Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "Do you practice Eyechiatry? The psychology of vision loss," which he co-presented with Roya Attar, OD, MBA.

Roya Attar, OD, discussed, "White dot syndrome: More common than you think," which she will be presenting at AOA 2023 in Washington, DC.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

Jessica Haynes, OD, shares highlights from her 2023 AOA Optometry's Meeting presentation, "Application of angiography."

The organization aims to educate viewers of dangers and safety precautions ahead of the eclipses.

Lattice retinal degeneration is the most significant peripheral retinal change associated with retinal detachment. Generally, it is a stable condition without symptoms unless the complication of a retinal tear develops, which can lead to retinal detachment. There are a number of presentations among patients, who can be of a young age and have almost any refractive correction.

Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.

Insights for eye care providers.

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

It is important that clinicians are prepared with alternative methods for patients experiencing refractory CME after failed improvement with the agents that are most frequently used.

The DR:EAM study in investigating novel eye drop OTT-166 for the treatment of diabetic retinopathy in hopes of reducing treatment burden for patients.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Umida F. Mavlyanova, PhD, in a presentation at the American Society for Cataract and Refractive Surgery’s annual meeting in San Diego, detailed how patients diagnosed with end-stage chronic renal failure displayed deceased blood flow in the orbital artery, the central artery of the retina and the posterior short ciliary arteries.

Leo Semes, OD, shares highlights from his presentation on early detection of AMD, which he presented during the 17th annual Controversies in Modern Eye Care.

David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.

In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.

Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.

Euin Cheong, OD, weighs in on the Syfvore approval for geographic atrophy and how optometrists should participate in geographic atrophy care.

Imaging can elucidate visual prognosis and disease progression risk.

In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.

These disorders account for most of the vision loss in working-age and elderly Americans.

Mohammad Rafieetary, OD, shares key highlights from his VEE 2023 presentation looking at what's hot in retina.

Paul Chous, MA, OD, FAAO, shares key highlights from his 2023 SECO presentation looking at sleep disorders and how they play a role in eye disease.

Andy Lee, MD, gives highlights from his SECO special session, "Neuro nuggets."

Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."

Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.